TABLE 4.
Stratified multivariate analyses for association between unfavorable genotypes and OS in NSCLC patients in the PLCO trial
| Characteristics | No. of 0 risk genotypes | No. of 1–2 risk genotypes | Multivariate analysisa | Pinterb | ||||
|---|---|---|---|---|---|---|---|---|
| All | Death (%) | All | Death (%) | HR (95% CI) | P | |||
| Age (years) | ||||||||
| ≤ 71 | 277 | 168 (60.7) | 357 | 251 (64.7) | 1.31 (1.07–1.61) | 0.009 | ||
| > 71 | 239 | 166 (69.5) | 302 | 224 (74.2) | 1.35 (1.10–1.65) | 0.005 | 0.697 | |
| Sex | ||||||||
| Male | 273 | 190 (69.6) | 422 | 315 (74.6) | 1.33 (1.11–1.60) | 0.002 | ||
| Female | 243 | 144 (59.3) | 237 | 140 (59.1) | 1.32 (1.03–1.69) | 0.029 | 0.906 | |
| Smoking status | ||||||||
| Never | 57 | 28 (49.1) | 57 | 34 (59.7) | 1.44 (0.81–2.57) | 0.212 | ||
| Current | 182 | 110 (60.4) | 235 | 156 (66.4) | 1.72 (1.33–2.23) | <0.001 | ||
| Former | 277 | 196 (70.8) | 367 | 265 (72.2) | 1.08 (0.90–1.31) | 0.409 | 0.002* | |
| Histology | ||||||||
| Adenocarcinoma | 259 | 149 (57.5) | 316 | 197 (62.3) | 1.36 (1.09–1.70) | 0.007 | ||
| Squamous | 129 | 87(67.4) | 155 | 104 (67.1) | 1.32 (0.98–1.79) | 0.069 | ||
| Others | 128 | 98 (76.6) | 188 | 154 (81.9) | 1.43 (1.10–1.87) | 0.009 | 0.780 | |
| Tumor stage | ||||||||
| I-IIB | 287 | 133 (46.3) | 367 | 181 (49.3) | 1.23 (0.98–1.55) | 0.077 | ||
| IIIA-IV | 229 | 201 (87.8) | 292 | 274 (93.8) | 1.36 (1.12–1.64) | 0.002 | 0.524 | |
| Chemotherapy | ||||||||
| No | 272 | 147 (54.0) | 366 | 219 (59.8) | 1.33 (1.07–1.65) | 0.009 | ||
| Yes | 244 | 187 (76.6) | 293 | 236 (80.6) | 1.22 (1.00–1.50) | 0.049 | 0.847 | |
| Radiotherapy | ||||||||
| No | 323 | 179 (55.4) | 438 | 270 (61.6) | 1.35 (1.11–1.64) | 0.002 | ||
| Yes | 193 | 155 (80.3) | 221 | 185 (83.7) | 1.25 (1.00–1.56) | 0.055 | 0.397 | |
| Surgery | ||||||||
| No | 283 | 242 (85.5) | 352 | 323 (91.8) | 1.34 (1.13–1.59) | 0.0008 | ||
| Yes | 233 | 92 (39.5) | 307 | 132 (43.0) | 1.33 (1.01–1.76) | 0.041 | 0.771 | |
| Phenotype missingc | 10 | |||||||
Abbreviations: CI = Confidence interval; HR = Hazards ratio; NSCLC = Non-small cell lung cancer; OS = Overall survival; PLCO = Prostate, Lung, Colorectal and Ovarian cancer trial.
a
Adjusted for age, sex, stage, histology, smoking status, chemotherapy, radiotherapy, surgery, PC1, PC2, PC3 and PC4;
b
Pinter: P-value for interaction analysis between characteristic and number of protective genotypes;
c
Two observations missing of tumor stage and eight observations missing of chemotherapy/radiotherapy/surgery in PLCO dataset.